These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 22764210

  • 1. Letter by Stollberger and Finsterer regarding article, "intracranial hemorrhage in patients with atrial fibrillation during anticoagulation with Warfarin or Dabigatran: the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial".
    Stöllberger C, Finsterer J.
    Stroke; 2012 Sep; 43(9):e93. PubMed ID: 22764210
    [No Abstract] [Full Text] [Related]

  • 2. Letter by Freeman et al regarding article, "Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY Trial".
    Freeman WD, Kuo R, Aguilar MI.
    Stroke; 2012 Jul; 43(7):e63. PubMed ID: 22618385
    [No Abstract] [Full Text] [Related]

  • 3. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial.
    Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA, Ezekowitz MD, Yusuf S.
    Stroke; 2012 Jun; 43(6):1511-7. PubMed ID: 22492518
    [Abstract] [Full Text] [Related]

  • 4. Letter by Reiffel regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".
    Reiffel JA.
    Circulation; 2012 Jan 24; 125(3):e292; author reply e293-4. PubMed ID: 22271858
    [No Abstract] [Full Text] [Related]

  • 5. Letter by Govindarajan and Salgado regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".
    Govindarajan R, Salgado E.
    Circulation; 2012 Jan 24; 125(3):e290; author reply e293-4. PubMed ID: 22271856
    [No Abstract] [Full Text] [Related]

  • 6. Letter by Reynolds et al regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".
    Reynolds S, Parra D, Rosenstein RS.
    Circulation; 2012 Jan 24; 125(3):e291; author reply e293-4. PubMed ID: 22271857
    [No Abstract] [Full Text] [Related]

  • 7. Response to letter regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis".
    Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L.
    Circulation; 2014 Nov 25; 130(22):e195. PubMed ID: 25421051
    [No Abstract] [Full Text] [Related]

  • 8. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
    Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S.
    Circulation; 2011 May 31; 123(21):2363-72. PubMed ID: 21576658
    [Abstract] [Full Text] [Related]

  • 9. Letter by Chin et al regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis".
    Chin PK, Wright DF, Florkowski CM.
    Circulation; 2014 Nov 25; 130(22):e194. PubMed ID: 25421050
    [No Abstract] [Full Text] [Related]

  • 10. Response to letter regarding article, "Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control".
    Chan PH, Hai JJ, Siu CW.
    Stroke; 2015 Mar 25; 46(3):e72. PubMed ID: 25649808
    [No Abstract] [Full Text] [Related]

  • 11. Letter by Feng et al regarding article, "Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control".
    Feng X, Huan Y, Lv Y.
    Stroke; 2015 Mar 25; 46(3):e71. PubMed ID: 25649800
    [No Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.
    Ann Intern Med; 2011 Jan 04; 154(1):1-11. PubMed ID: 21041570
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
    Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L.
    Circulation; 2014 Mar 04; 129(9):961-70. PubMed ID: 24323795
    [Abstract] [Full Text] [Related]

  • 14. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control.
    Ho CW, Ho MH, Chan PH, Hai JJ, Cheung E, Yeung CY, Lau KK, Chan KH, Lau CP, Lip GY, Leung GK, Tse HF, Siu CW.
    Stroke; 2015 Jan 04; 46(1):23-30. PubMed ID: 25406148
    [Abstract] [Full Text] [Related]

  • 15. Intensity and quality of warfarin anticoagulation in Chinese patients: setting the record straight.
    Eikelboom JW, Hart RG.
    Stroke; 2015 Jan 04; 46(1):5-6. PubMed ID: 25406147
    [No Abstract] [Full Text] [Related]

  • 16. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.
    Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, Flaker G, Brugada J, Kamensky G, Parekh A, Reilly PA, Yusuf S, Connolly SJ.
    Circulation; 2011 Jan 18; 123(2):131-6. PubMed ID: 21200007
    [Abstract] [Full Text] [Related]

  • 17. Letter by Hjemdahl et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial".
    Hjemdahl P, Johnsson H, Wallén NH.
    Circulation; 2013 Mar 19; 127(11):e505. PubMed ID: 23509038
    [No Abstract] [Full Text] [Related]

  • 18. Letter by David et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) Randomized Trial".
    David JS, Piriou V, Albaladejo P.
    Circulation; 2013 Mar 19; 127(11):e504. PubMed ID: 23509037
    [No Abstract] [Full Text] [Related]

  • 19. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA.
    Circulation; 2015 Jan 13; 131(2):157-64. PubMed ID: 25359164
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
    Kamel H, Johnston SC, Easton JD, Kim AS.
    Stroke; 2012 Mar 13; 43(3):881-3. PubMed ID: 22308255
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.